| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Arthritis (rheumatoid)TocilizumabPsoriasisUstekinumabArthritis (juvenile idiopathic)Interleukin6Inflammation (BASKET)Receptor (Interleukin6 GP130)| 1 | 2008 | Review of tocilizumab in the treatment of rheumatoid arthritis. | 
| + | - | nl | Biologics 2(1):75-82 (2008) Okuda Y |
| 2 | 2010 | Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. |
| + | - | nl | J Manag Care Pharm 16(6):402-16 (2010) Schafer JA |
| 3 | 2007 | Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. |
| + | - | nl | Biol Pharm Bull 30(11):2001-6 (2007) |
| 4 | 2010 | Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. |
| + | - | nl | Ther Clin Risk Manag 6():143-52 (2010) Hushaw LL |
| 5 | 2010 | Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis. |
| + | - | nl | Core Evid 4():181-9 (2010) Herlin T |
| 6 | 2010 | Tocilizumab - a new step in rheumatoid arthritis treatment. |
| + | - | nl | Acta Reumatol Port 35(3):302-12 (2010) |
| 7 | 2007 | Interleukin-6 inhibition--tolerability profile and clinical implications. |
| + | - | nl | Bull NYU Hosp Jt Dis 65 Suppl 1(-):S21-4 (2007) |
| 8 | 2011 | Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. |
| + | - | nl | J Clin Invest 121(9):3375-83 (2011) |
